The experimental coronavirus treatment remdesivir has failed in its first randomized clinical trial, inadvertently released results showed on Thursday, dampening expectations for the closely watched drug.
A draft summary went online briefly on the WHO Web site and was first reported by the Financial Times and health news Web site Stat, which posted a screenshot.
However, Gilead Sciences, the company behind the medicine, disputed how the now-deleted post had characterized the findings, saying that the data showed a “potential benefit.”
Photo: AFP
The Chinese trial involved 237 patients, with 158 on the drug and 79 in a control group, the summary said, adding that remdesivir was stopped early in 18 patients because of side effects.
The authors said that remdesivir was “not associated with a difference in time to clinical improvement” compared with the control.
After a month, 13.9 percent of the patients on remdesivir had died, compared with 12.8 percent of those in the control group. The difference is not statistically significant.
The WHO told the Financial Times that the draft is undergoing peer review and was published early in error.
“We believe the post included inappropriate characterizations of the study,” a Gilead spokesman told reporters, adding that it was terminated early due to low enrollment and was therefore not statistically meaningful.
“As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease,” the spokesman said.
The study does not represent the final word on the matter, and there are several large-scale trials in advanced stages that should soon provide a clearer picture.
Remdesivir, which is administered intravenously, was among the first drugs suggested as a treatment for the novel coronavirus and as such has great hopes riding on it.
Last week, Stat reported that it had shown significant efficacy at a Chicago hospital where patients who are part of one of the major trials are being treated.
The US National Institutes of Health also reported it that had proven effective in a small experiment on monkeys.
Remdesivir, which previously failed in trials against Ebola, belongs to a class of drugs that act on the virus directly — as opposed to controlling the abnormal and often lethal autoimmune response it causes. It mimics one of the four building blocks of RNA and DNA, and gets absorbed into the virus’ genome, which in turn stops the pathogen from replicating.
Anti-malarial drugs hydroxychloroquine and chloroquine have also been widely used on COVID-19 on a so-called “compassionate basis” pending results from large trials, with early studies decidedly mixed.
Other therapies that are being studied include collecting antibodies from COVID-19 survivors and injecting them in patients, or harvesting antibodies from genetically engineered mice that were deliberately infected.
Separately in France, new research shows that nicotine could protect people from contracting COVID-19.
The findings came after researchers at a top Paris hospital examined 343 COVID-19 patients, as well as 139 people with the illness who had milder symptoms.
They found that a low number of them smoked, compared with smoking rates of about 35 percent in France’s general population.
“Among these patients, only 5 percent were smokers,” said Zahir Amoura, the study’s coauthor and a professor of internal medicine.
The research echoed similar findings published in the New England Journal of Medicine last month suggesting that 12.6 percent of 1,000 people infected in China were smokers.
That was a much lower figure than the number of regular smokers in China’s general population, about 26 percent, WHO data showed.
The theory is that nicotine could adhere to cell receptors, therefore blocking the novel coronavirus from entering cells and spreading in the body, said neurobiologist Jean-Pierre Changeux from France’s Pasteur Institute, who also coauthored the study.
The researchers are awaiting approval from health authorities to carry out further clinical trials.
The researchers are looking into whether nicotine could help to prevent “cytokine storms,” a rapid overreaction of the immune system that scientists think could play a key role in fatal COVID-19 cases.
However, with further research needed, experts are not encouraging people to pick up smoking or use nicotine patches as a protective measure against the virus.
“We must not forget the harmful effects of nicotine,” French Director-General for Health Jerome Salomon said.
“Those who do not smoke should absolutely not use nicotine substitutes,” which cause side effects and addiction, he said.
The Burmese junta has said that detained former leader Aung San Suu Kyi is “in good health,” a day after her son said he has received little information about the 80-year-old’s condition and fears she could die without him knowing. In an interview in Tokyo earlier this week, Kim Aris said he had not heard from his mother in years and believes she is being held incommunicado in the capital, Naypyidaw. Aung San Suu Kyi, a Nobel Peace Prize laureate, was detained after a 2021 military coup that ousted her elected civilian government and sparked a civil war. She is serving a
REVENGE: Trump said he had the support of the Syrian government for the strikes, which took place in response to an Islamic State attack on US soldiers last week The US launched large-scale airstrikes on more than 70 targets across Syria, the Pentagon said on Friday, fulfilling US President Donald Trump’s vow to strike back after the killing of two US soldiers. “This is not the beginning of a war — it is a declaration of vengeance,” US Secretary of Defense Pete Hegseth wrote on social media. “Today, we hunted and we killed our enemies. Lots of them. And we will continue.” The US Central Command said that fighter jets, attack helicopters and artillery targeted ISIS infrastructure and weapon sites. “All terrorists who are evil enough to attack Americans are hereby warned
Seven wild Asiatic elephants were killed and a calf was injured when a high-speed passenger train collided with a herd crossing the tracks in India’s northeastern state of Assam early yesterday, local authorities said. The train driver spotted the herd of about 100 elephants and used the emergency brakes, but the train still hit some of the animals, Indian Railways spokesman Kapinjal Kishore Sharma told reporters. Five train coaches and the engine derailed following the impact, but there were no human casualties, Sharma said. Veterinarians carried out autopsies on the dead elephants, which were to be buried later in the day. The accident site
‘NO AMNESTY’: Tens of thousands of people joined the rally against a bill that would slash the former president’s prison term; President Lula has said he would veto the bill Tens of thousands of Brazilians on Sunday demonstrated against a bill that advanced in Congress this week that would reduce the time former president Jair Bolsonaro spends behind bars following his sentence of more than 27 years for attempting a coup. Protests took place in the capital, Brasilia, and in other major cities across the nation, including Sao Paulo, Florianopolis, Salvador and Recife. On Copacabana’s boardwalk in Rio de Janeiro, crowds composed of left-wing voters chanted “No amnesty” and “Out with Hugo Motta,” a reference to the speaker of the lower house, which approved the bill on Wednesday last week. It is
RSS